Amgen Inc.
NASDAQ:AMGNDrug Manufacturers - General
-$6.93 today
- Market cap
- $240.11B
- Beta
- 0.42
- P/E (TTM)
- 23.2
- EPS (TTM)
- $14.44
- Dividend yield
- 2.93%
Volume 2.58M
Average 2.76M
AMGN EBITDA Margin
EBITDA as a percentage of revenue.
Amgen Inc.NASDAQ: AMGN
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin widens to 45.3%
EBITDA Margin was 45.3% in Q2 FY2026, up 5.8 pp from a year earlier. On a trailing-twelve-month basis it was 46.2%, up 0.7 pp year over year. Over 3 fiscal years it narrowed by 0.2 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 22 analysts of 55.7% for the fiscal year ending Dec 2026, up from 46.0% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- 45.3%+0.5 pp QoQ
- Last fiscal yearDec 2025
- 46.0%+6.0 pp YoY
- LTMJun 2026
- 46.2%+0.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +5.8 pp | -8.4 pp | -14.2 pp |
| 1 year | +6.0 pp | +9.7 pp | +3.7 pp |
| 3 years | -0.2 pp | +7.0 pp | +7.3 pp |
| 5 years | +7.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 46.0%
- Year-over-year change
- +6.0pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.0% | +6.0pp |
| FY2024 | 2024-12-31 | 40.0% | -12.5pp |
| FY2023 | 2023-12-31 | 52.5% | +6.3pp |
| FY2022 | 2022-12-31 | 46.2% | +2.7pp |
| FY2021 | 2021-12-31 | 43.5% | — |
EBITDA Margin vs competitors
How AMGN compares with its peers on the latest reported figures
- AMGN's LTM Jun 2026 EBITDA Margin of 46.2% is the 2nd highest of the 10 companies compared; the peer median is 34.2%.
- Its year-over-year change of +0.7 pp is the 5th highest of 10, against a peer median of -0.7 pp.
- Over three fiscal years its change of -0.2 pp compares with a peer median of +7.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 54.4% | +14.4 pp | +18.3 pp | |
| LTM Jun 2026 | 46.2% | +0.7 pp | -0.2 pp | |
| LTM Jun 2026 | 40.0% | -1.1 pp | +8.2 pp | |
| LTM Sep 2026 | 36.6% | +15.1 pp | -12.8 pp | |
| LTM Sep 2026 | 34.4% | +3.4 pp | +13.3 pp | |
| LTM Jun 2026 | 34.2% | +2.6 pp | -10.0 pp | |
| LTM Sep 2026 | 31.0% | -11.9 pp | +10.3 pp | |
| LTM Jun 2026 | 26.5% | -0.7 pp | +2.5 pp | |
| LTM Jun 2026 | 21.2% | -10.4 pp | -13.7 pp | |
| LTM Jun 2026 | 21.0% | -18.3 pp | +7.6 pp | |
| Peer median (excluding AMGN) | 34.2% | -0.7 pp | +7.6 pp | |
Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 25.98B | 26.32B | 28.19B | 33.42B | 36.74B |
| Cost of Revenue | 6.45B | 6.41B | 8.42B | 12.86B | 10.73B |
| Gross Profit | 19.53B | 19.92B | 19.78B | 20.57B | 26.01B |
| Gross Margin | 75.2% | 75.7% | 70.1% | 61.5% | 70.8% |
| Research & Development | 6.32B | 4.43B | 4.78B | 5.96B | 6.97B |
| Selling, General & Admin | 5.37B | 5.41B | 6.18B | 7.1B | 7.05B |
| Operating Expenses | 11.89B | 10.35B | 11.84B | 13.31B | 15.34B |
| Depreciation & Amortization | 3.4B | 3.42B | 4.07B | 5.59B | 5.17B |
| EBITDA | 11.3B | 12.17B | 14.8B | 13.36B | 16.9B |
| EBITDA Margin | 43.5% | 46.2% | 52.5% | 40.0% | 46.0% |
| Operating Income | 7.64B | 9.57B | 7.9B | 7.26B | 10.68B |
| Operating Margin | 29.4% | 36.3% | 28.0% | 21.7% | 29.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 1.2B | 1.41B | 2.88B | 3.16B | 2.76B |
| Other Income / Expenses | (938M) | (2.22B) | (42M) | (2.65B) | (1.7B) |
| Income Before Tax | 6.7B | 7.35B | 7.86B | 4.61B | 8.98B |
| Pre-Tax Margin | 25.8% | 27.9% | 27.9% | 13.8% | 24.4% |
| Income Tax Expense | 808M | 794M | 1.14B | 519M | 1.27B |
| Net Income | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B |
| Net Margin | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% |
| EPS (Basic) | 10.34 | 12.18 | 12.56 | 7.62 | 14.33 |
| EPS (Diluted) | 10.28 | 12.11 | 12.49 | 7.56 | 14.23 |
| Weighted Avg Shares | 570M | 538M | 535M | 541M | 538M |
| Weighted Avg Shares (Diluted) | 573M | 541M | 538M | 541M | 542M |
Amgen Inc.
NASDAQ:AMGN
Intrinsic Alpha fair value
Locked
Current Price
$443.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.